Humanized Anti-MUC16 Recombinant V-kappa Antibody (TAB-H63) (CAT#: TAB-H63)

Rasoulouniriana, Diana, et al. "T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors." Cancer Immunology Research 11.6 (2023): 792-809. https://doi.org/10.1158/2326-6066.CIR-22-0423

The study focused on engineering a modified FcgRI receptor for T cells, aiming to enhance their antibody-dependent cytotoxicity (ADCC) against solid tumors. This new receptor allows T cells to target tumor cells using antibodies, demonstrating effective and specific cytotoxicity only in the presence of appropriate antibodies. The engineered T cells, tested in both immunocompetent and immunodeficient mice, showed significant tumor eradication while secreting lower levels of cytokines compared to traditional CAR T cells, thus enhancing their safety profile. This technology offers a versatile approach, enabling the same engineered T cells to target different tumors by simply changing the injected antibody.
Creative Biolabs contributed by providing several critical antibodies for the study. Specifically, Creative Biolabs supplied Sofituzumab (Cat#: TAB-H63) and Necitumumab (Cat#: TAB-119). These antibodies were essential for testing the ADCC capabilities of the modified T cells, as they facilitated the targeting of specific tumor antigens, demonstrating the versatility and efficacy of the engineered T cells in preclinical models.